 | Nirmatrelvir (redirect from PF-07321332) February 2021, Pfizer launched the company's first phase I trial of PF-07321332 (nirmatrelvir) at its clinical research unit in New Haven, Connecticut... 24 KB (1,910 words) - 17:27, 25 February 2024 |
| 2022. Retrieved 25 April 2022. "EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in... 64 KB (5,751 words) - 07:52, 24 March 2024 |
 | CLpro-1, GC376, rupintrivir, lufotrelvir, PF-07321332, and AG7404. The intravenous administered prodrug PF-07304814 (lufotrelvir) entered clinical trials... 21 KB (2,048 words) - 12:43, 27 December 2023 |
QU, Kim MS, Choi S (August 2021). "Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding... 15 KB (1,168 words) - 04:21, 24 December 2023 |
 | QU, Kim MS, Choi S (August 2021). "Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding... 41 KB (3,407 words) - 13:51, 21 January 2024 |
 | COVID Plan and announces that two antiviral treatments, Molnupiravir and PF-07321332/ritonavir, are in the testing phase and could be ready for deployment... 321 KB (39,682 words) - 19:23, 1 January 2024 |